Related Experiment Video
Updated: Jun 27, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Engineering the Future of ADCs in Non-Small Cell Lung Cancer
Mi Rim Kim1, Jason Lau1, Michele Maffezzoli2
1Oncology Unit, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
Oncology Research
|June 26, 2026
Summary
Next-generation antibody-drug conjugates (ADCs) improve non-small cell lung cancer (NSCLC) treatment by refining biomarkers and antibody engineering. These advanced ADCs offer enhanced efficacy and reduced toxicity for precision oncology in NSCLC.
Area of Science:
- Oncology
- Biotechnology
- Pharmacology
Background:
- Early antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) faced limitations including suboptimal targeting, variable drug-antibody ratios, and unstable linkers, leading to modest outcomes and toxicities.
- The development of ADCs in NSCLC has been hindered by challenges in patient selection and drug delivery mechanisms.
Purpose of the Study:
- To critically analyze the evolving biomarker landscape and engineering strategies for next-generation ADC development in NSCLC.
- To review emerging technologies for target identification, patient selection, and ADC optimization.
Main Methods:
- A narrative review of literature from PubMed and major oncology congresses up to October 2025.
- Analysis of emerging biomarker strategies (digital pathology, AI, transcriptomics, proteomics, liquid biopsy) and antibody engineering advancements (site-specific conjugation, linker chemistry).
Main Results:
- Next-generation ADCs leverage advanced biomarkers for improved target selection and patient stratification.
- Innovations in site-specific conjugation ensure homogeneous drug-to-antibody ratios (DAR), enhancing predictability and reducing off-target effects.
- Improved linker chemistry balances plasma stability with efficient payload release, optimizing the bystander effect and safety profile.
Conclusions:
- Next-generation ADCs in NSCLC integrate refined biomarkers with enhanced antibody engineering, linker design, and payload biology.
- Emerging strategies like immune-stimulating, bispecific ADCs, novel payloads, and combinations with TKIs or immunotherapy hold promise for improved efficacy and overcoming resistance.
- Advanced ADCs are poised to become a cornerstone of precision oncology in NSCLC, offering enhanced therapeutic windows and overcoming resistance mechanisms.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...